Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients
NCT ID: NCT05524467
Last Updated: 2024-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3100 participants
OBSERVATIONAL
2023-02-02
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiparametric MRI in Healthy Volunteers and CKD Patients
NCT05229263
The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe
NCT02187432
Description of Treatment Patterns and Population Characteristics of Pre-dialysis CKD Patients in the Czech Republic
NCT05380843
Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa
NCT03458338
Cohort Follow-up: Progression and Consequences of Chronic Kidney Disease.
NCT04070885
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The CENSUS-EU represents a cross-sectional study design of a representative selection of patients undergoing HD at 113 large dialysis centres across 7 countries in Europe. Prot. v.2.0, 9 May 2023
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Haemodialysis Patients
Only one data collection timepoint per patient is planned. Eligible and consenting patients will be asked to complete several PROs and one questionnaire, and their respective medical charts will be assessed retrospectively
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent
* Able and willing to fill in questionnaires
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vifor (International) Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Burton, Prof.
Role: PRINCIPAL_INVESTIGATOR
University of Leicester Leicester, United Kingdom
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1113
Aschaffenburg, , Germany
1011
Balingen, , Germany
1007
Braunschweig, , Germany
1016
Einbeck, , Germany
1012
Eisenach, , Germany
1043
Flensburg, , Germany
1048
Freiburg im Breisgau, , Germany
1049
Freiburg im Breisgau, , Germany
1046
Hanover, , Germany
1001
Herne, , Germany
1035
Kiel, , Germany
1111
Leipzig, , Germany
1013
Mainz, , Germany
1047
Saalfeld, , Germany
1053
Sömmerda, , Germany
1044
Witten, , Germany
1051
Wuppertal, , Germany
4027
Acquaviva delle Fonti, , Italy
4015
Bari, , Italy
4010
Civitavecchia, , Italy
4001
Florence, , Italy
4005
Lecce, , Italy
4016
L’Aquila, , Italy
4008
Macerata, , Italy
4023
Mestre, , Italy
4006
Milan, , Italy
4018
Milan, , Italy
4021
Milan, , Italy
4011
Modena, , Italy
4009
Monza, , Italy
4003
Palermo, , Italy
4017
Parma, , Italy
4006
Pavia, , Italy
4028
Pisa, , Italy
4002
Pistoia, , Italy
4026
Reggio Calabria, , Italy
4014
Roma, , Italy
4024
Rome, , Italy
4022
Treviso, , Italy
4030
Trieste, , Italy
4012
Verona, , Italy
4025
Viterbo, , Italy
5014
Cascais, , Portugal
5001
Faro, , Portugal
5013
Gandra, , Portugal
5011
Gondomar, , Portugal
5006
Leiria, , Portugal
5008
Porto, , Portugal
5002
Sacavém, , Portugal
3009
Palma de Mallorca, Mallorca, Spain
3006
Almería, , Spain
3005
Barcelona, , Spain
3011
Barcelona, , Spain
3012
Barcelona, , Spain
3026
Barcelona, , Spain
3002
Benidorm, , Spain
3008
Cadiz, , Spain
3001
Gijón, , Spain
3018
Granada, , Spain
3025
Jaén, , Spain
3020
Las Palmas, , Spain
3021
León, , Spain
3015
Madrid, , Spain
3016
Madrid, , Spain
3022
Madrid, , Spain
3024
Madrid, , Spain
3017
Pamplona, , Spain
3013
Santander, , Spain
3007
Seville, , Spain
3023
Seville, , Spain
3010
Terrassa, , Spain
3003
Valencia, , Spain
3004
Valencia, , Spain
3027
Valencia, , Spain
6008
Linköping, , Sweden
6007
Malmo, , Sweden
6005
Norrköping, , Sweden
6004
Örebro, , Sweden
6001
Stockholm, , Sweden
6003
Trollhättan, , Sweden
6006
Umeå, , Sweden
6002
Uppsala, , Sweden
2009
Baden, , Switzerland
2001
Bern, , Switzerland
2002
Frauenfeld, , Switzerland
2004
Lugano, , Switzerland
2003
Zurich, , Switzerland
7002
Bradford, , United Kingdom
7003
Hull, , United Kingdom
7001
Leicester, , United Kingdom
7006
London, , United Kingdom
7007
London, , United Kingdom
7005
Nottingham, , United Kingdom
7004
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS-DFK-2021-0712
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.